The Food and Drug Administration has approved a new treatment for gout, Krystexxa (pegloticase), an enzyme that lowers uric acid levels by metabolising it into a harmless chemical excreted in urine. The developer is Savient Pharmaceuticals Inc. ---Subscribe to MedNous to access this article--- Regulation & Policy
